AVI BioPharma, Inc., a developer of RNA-based drugs, today announced it secured increased funding of up to approximately $4.0 million under its agreement with the US Defense Threat Reduction Agency to develop, in cooperation with the Transformational Medical Technologies Initiative of the Department of Defense, one or more of AVI's nucleotide-based drug candidates targeting the pandemic H1N1 influenza virus.
AVI Biopharma secures increased funding of approximately $4.0 million